Clinical trial · no report yet · Phase 3
DUO-O
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
- NCT03737643 ↗
- Active not recruiting
- AstraZeneca
- 78 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 36 | |
| Podcasts | 21 | |
| X threads | 20 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Bevacizumab; Durvalumab; Olaparib; Placebo olaparib; Durvalumab placebo; Carboplatin+Paclitaxel
- Arms
- Arm 1 · Active comparator
- Arm 2 · Experimental
- Arm 3 · Experimental
- tBRCAm cohort · Experimental
- Enrollment
- 1,407
- Primary outcomes
- Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
- Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)
- Sponsor
- AstraZeneca with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Myriad Genetic Laboratories, Inc.
- Start
- Jan 4, 2019
- Primary completion
- Mar 17, 2025
- Results posted
- Yes
- Registry record
- NCT03737643 · updated Jul 7, 2026
Publications
linked from the registry- Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. PubMed 37185961